Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.
A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.
We briefly summarize some of the most noteworthy new HIV treatment studies presented at a major research conference that took place this month.
Stribild, compared to Atripla, was efficacious, durable, well-tolerated and safe in treatment-naive Black adults, and may be a viable switch option for virologically suppressed Black patients looking for regimen modification or simplification.
So with all the positive news about integrase inhibitors in initial HIV treatment, is it safe to switch patients from other NNRTI (non-nucleoside reverse transcriptase inhibitor)- or PI (protease inhibitor)-based regimens to integrase inhibitor regim...
A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.
As the HIV community grows older, the HIV research spotlight is shifting with it. A special study of the newly approved four-in-one pill Stribild compared how well the drug works in HIVers over 50 compared to younger people.
The newly approved four-in-one drug Stribild appears to show somewhat better effectiveness and tolerability than either Atripla or a regimen comprised of Norvir, Reyataz and Truvada, according to combined results from three 48-week studies.
Gilead Sciences Inc.'s experimental pill combining four HIV drugs has fewer side effects than the firm's current three-drug Atripla pill, according to data presented Wednesday in Seattle at the 19th Conference on Retroviruses and Opportunistic Infect...
Data Show Gilead's Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study
Seattle, Wash. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full results from the second pivotal Phase 3 clinical trial (Study 103) of its Quad once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disop...